Salience Clinical Introduces S2G Framework Pairing AI Screening with Physician-Executive GestaltSubmissions
New methodology provides biopharma and medtech sponsors an auditable path from multimodal clinical data entropy to regulatory-ready narratives.
PRINCETON, N.J., United States, 15th Sep 2026 – Salience Clinical, LLC, a clinical development and regulatory advisory consultancy, today announced the launch of the Salience Signal-to-Gestalt (S2G) Framework. The methodology addresses a major industry pain point: clinical programs produce massive amounts of digital biomarkers, sensor data, and real-world evidence (RWE) that create an unmanageable flood of false signals using conventional statistical tools, while opaque machine learning algorithms fail to provide regulators the biological plausibility and audit trail they demand.
This problem is addressed by the S2G Framework, which employs a fo...